Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

NCT04221555 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Docetaxel, Oxaliplatin, S-1 and Durvalumab
DRUG: Durvalumab and Tremelimumab

Sponsor

Asan Medical Center